Related Experiment Video
Updated: Jun 7, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications
Darsshen Ramana A L Kathirasan1, Siti Nor 'Izzah Binti Normizan2, Nurul Athirah Binti Mohd Salleh2
1Faculty Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, 30450 Ipoh, Perak, Malaysia; Pharmacy Department, Hospital Raja Permaisuri Bainun, Jalan Raja Ashman Shah, 30450 Ipoh, Perak, Malaysia.
Abstract:
Toll-like receptor 4 (TLR4) plays a vital role in the innate immune response, but its overactivation has been associated with several diseases, such as aggressive progression of triple-negative breast cancer (TNBC). As a result, inhibiting TLR4 has emerged as a potential therapeutic strategy for this challenging breast cancer subtype. This review summarizes recent advancements in the development of small-molecule TLR4 antagonists to suppress TNBC growth, metastasis, and chemotherapy resistance. We also examine their potential in managing cancer-related complications and propose future directions for their application in TNBC therapy.
Insights
Small-molecule inhibitors targeting Toll-like receptor 4 (TLR4) show promise for treating triple-negative breast cancer (TNBC). These compounds aim to suppress tumor growth, metastasis, and resistance to chemotherapy, offering new therapeutic avenues.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Toll-like receptor 4 (TLR4) is crucial for innate immunity.
- TLR4 overactivation is linked to aggressive triple-negative breast cancer (TNBC) progression.
- Inhibiting TLR4 presents a potential therapeutic strategy for TNBC.
Purpose of the Study:
- To review recent advancements in small-molecule TLR4 antagonists for TNBC.
- To explore the potential of these antagonists in suppressing TNBC growth, metastasis, and chemotherapy resistance.
- To examine their role in managing cancer-related complications and suggest future therapeutic directions.
Main Methods:
- Literature review of recent studies on small-molecule TLR4 antagonists.
- Analysis of preclinical and clinical data regarding TLR4 inhibition in TNBC models.
- Synthesis of information on therapeutic potential and future applications.
Main Results:
- Several small-molecule TLR4 antagonists have been developed.
- These antagonists demonstrate potential in inhibiting TNBC progression and overcoming chemotherapy resistance.
- Emerging evidence suggests utility in managing cancer-related complications.
Conclusions:
- Small-molecule TLR4 antagonists are promising therapeutic agents for TNBC.
- Further research is warranted to optimize their application and clinical translation.
- Targeting TLR4 offers a novel strategy to improve outcomes for TNBC patients.
